

web: <http://covidcirrhosis.org>
email: covid.cirrhosis@unc.edu
twitter: @SecureCirrhosis

web: <https://covid-hep.net>
email: info@covid-hep.net
twitter: @COVIDHep

Combined weekly update – 21 Apr 2020

We continue to wish everyone working to fight COVID-19 well and we welcome you to this combined update from our two collaborating international registries: **SECURE-Cirrhosis** covering The Americas, China/Japan/Korea and **COVID-Hep** covering the rest of the world in an attempt to collate clinical details of patients with chronic liver disease who develop COVID-19.


Submissions to date: 205 laboratory-proven cases, 123 (60%) men, median age of 61 years (IQR 48-69).

Cirrhosis (n = 118)

Major aetiologies

Alcohol	35	30%
Non alcoholic steatohepatitis	19	16%
Hepatitis B	14	12%
Hepatitis C	12	10%
Haemochromatosis	10	8%
Autoimmune hepatitis	6	5%

Submissions from 21 countries



Major outcomes

Intensive care admission	27	23%
Invasive ventilation	19	16%
Death	47	40%

Specific COVID-19 targeted therapy

Any	47	40%
Lopinovir/ritonavir	13	11%
Chloroquine/hydroxychloroquine	22	19%

Chronic liver disease without cirrhosis (n = 50)

Major outcomes

Intensive care admission	13	30%
Invasive ventilation	12	27%
Death	6	12%

Liver transplant (n = 37)

Major outcomes

Intensive care admission	8	27%
Invasive ventilation	7	23%
Death	8	22%

We look forward to providing more updates in future and thank all our contributors so far.